In HER-2 positive breast cancer patients receiving trastuzumab, both lisinopril and carvedilol reduced the incidence of cardiotoxicity by 47% and 51%, respectively, compared to placebo after 2 years of follow-up, in addition to concomitant anthracycline therapy [127]. The gene discussed is ERBB2; the disease is breast cancer.